Oncolytics Gross Profit from 2010 to 2024

ONCY Stock

USD 1.07 0.05 4.46%

Oncolytics Biotech Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about -423.1 K in 2024. Gross Profit is the profit Oncolytics Biotech makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2000-03-31

Previous Quarter

-123 K

Current Value

-98 K

Quarterly Volatility

969.8 K

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.

Check out the analysis of Oncolytics Biotech Correlation against competitors.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Oncolytics Biotech over the last few years. Gross profit is a required income statement account that reflects total revenue of Oncolytics Biotech minus its cost of goods sold. It is profit before Oncolytics Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Oncolytics Biotech's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

Oncolytics Gross Profit Regression Statistics

	Arithmetic Mean	(564,356)
	Geometric Mean	0.00
	Coefficient Of Variation	(236.27)
	Mean Deviation	636,030
	Median	(180,411)
	Standard Deviation	1,333,386
	Sample Variance	1.8T
	Range	5.3M
	R-Value	0.25
	Mean Square Error	1.8T
	R-Squared	0.06
	Significance	0.37
	Slope	74,918
	Total Sum of Squares	24.9T

Oncolytics Gross Profit History

	2024	-423.1 K
	2023	-403 K
	2022	-392 K
	2021	-452.1 K
	2020	-446.2 K
	2019	-485.6 K
	2018	-95.4 K

Other Fundumenentals of Oncolytics Biotech

Gross Profit Margin

Oncolytics Biotech Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Net Tangible Assets	Short Term Investments	Common Stock	Property Plant Equipment	Capital Surpluse	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.9	-0.84	-0.62	-0.07	-0.15	0.32	1.0	0.68	0.33	0.66	0.7	0.33	-0.65	0.79	0.79	0.73
Total Stockholder Equity	0.9		-0.8	-0.33	0.09	-0.33	-0.1	0.9	0.58	0.17	0.39	0.44	0.02	-0.38	0.75	0.73	0.54
Net Debt	-0.84	-0.8		0.43	0.0	0.25	-0.13	-0.85	-0.52	-0.07	-0.49	-0.53	-0.14	0.39	-0.6	-0.61	-0.48
Retained Earnings	-0.62	-0.33	0.43		0.36	-0.11	-0.6	-0.62	-0.78	-0.41	-0.99	-0.72	-0.8	0.81	-0.61	-0.64	-0.77
Accounts Payable	-0.07	0.09	0.0	0.36		-0.05	-0.29	-0.03	-0.52	-0.38	-0.37	-0.27	-0.61	0.61	-0.39	-0.43	-0.52
Net Receivables	-0.15	-0.33	0.25	-0.11	-0.05		0.43	-0.14	-0.11	-0.05	0.05	0.06	0.3	0.08	-0.18	-0.18	-0.14
Total Liab	0.32	-0.1	-0.13	-0.6	-0.29	0.43		0.33	0.16	0.44	0.54	0.72	0.68	-0.55	0.13	0.18	0.38
Total Current Assets	1.0	0.9	-0.85	-0.62	-0.03	-0.14	0.33		0.66	0.33	0.66	0.71	0.33	-0.62	0.77	0.77	0.7
Net Tangible Assets	0.68	0.58	-0.52	-0.78	-0.52	-0.11	0.16	0.66		0.32	0.82	0.57	0.64	-0.82	0.92	0.93	0.9
Short Term Investments	0.33	0.17	-0.07	-0.41	-0.38	-0.05	0.44	0.33	0.32		0.39	0.38	0.41	-0.48	0.34	0.36	0.39
Common Stock	0.66	0.39	-0.49	-0.99	-0.37	0.05	0.54	0.66	0.82	0.39		0.69	0.77	-0.84	0.66	0.69	0.81
Property Plant Equipment	0.7	0.44	-0.53	-0.72	-0.27	0.06	0.72	0.71	0.57	0.38	0.69		0.62	-0.7	0.62	0.65	0.65
Capital Surpluse	0.33	0.02	-0.14	-0.8	-0.61	0.3	0.68	0.33	0.64	0.41	0.77	0.62		-0.76	0.52	0.56	0.67
Current Deferred Revenue	-0.65	-0.38	0.39	0.81	0.61	0.08	-0.55	-0.62	-0.82	-0.48	-0.84	-0.7	-0.76		-0.76	-0.8	-0.96
Net Invested Capital	0.79	0.75	-0.6	-0.61	-0.39	-0.18	0.13	0.77	0.92	0.34	0.66	0.62	0.52	-0.76		1.0	0.87
Net Working Capital	0.79	0.73	-0.61	-0.64	-0.43	-0.18	0.18	0.77	0.93	0.36	0.69	0.65	0.56	-0.8	1.0		0.9
Capital Stock	0.73	0.54	-0.48	-0.77	-0.52	-0.14	0.38	0.7	0.9	0.39	0.81	0.65	0.67	-0.96	0.87	0.9

Click cells to compare fundamentals

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-403 K	-423.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC